News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,704 Results
Type
Article (40415)
Company Profile (291)
Press Release (671997)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (206661)
Career Advice (2024)
Deals (35774)
Drug Delivery (95)
Drug Development (82213)
Employer Resources (174)
FDA (16296)
Job Trends (15023)
News (349367)
Policy (32814)
Tag
Academia (2564)
Accelerated approval (10)
Adcomms (22)
Allergies (96)
Alliances (50223)
ALS (111)
Alzheimer's disease (1452)
Antibody-drug conjugate (ADC) (152)
Approvals (16297)
Artificial intelligence (313)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11738)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (205)
Bladder cancer (94)
Brain cancer (35)
Breast cancer (369)
Cancer (2887)
Cardiovascular disease (218)
Career advice (1691)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (502)
Cervical cancer (22)
Clinical research (67745)
Collaboration (1029)
Company closure (3)
Compensation (697)
Complete response letters (23)
COVID-19 (2635)
CRISPR (57)
C-suite (335)
Cystic fibrosis (113)
Data (3023)
Decentralized trials (2)
Denatured (20)
Depression (63)
Diabetes (346)
Diagnostics (6435)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (139)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (128)
Earnings (88397)
Editorial (41)
Employer branding (22)
Employer resources (150)
Events (115897)
Executive appointments (857)
FDA (17958)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (935)
Gene editing (130)
Generative AI (22)
Gene therapy (376)
GLP-1 (794)
Government (4518)
Grass and pollen (5)
Guidances (181)
Healthcare (18887)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (9)
Indications (40)
Infectious disease (2807)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (121)
Interviews (316)
IPO (16778)
IRA (44)
Job creations (3684)
Job search strategy (1433)
Kidney cancer (13)
Labor market (52)
Layoffs (497)
Leadership (18)
Legal (7956)
Liver cancer (79)
Longevity (12)
Lung cancer (400)
Lymphoma (210)
Machine learning (11)
Management (58)
Manufacturing (389)
MASH (91)
Medical device (13476)
Medtech (13481)
Mergers & acquisitions (19723)
Metabolic disorders (852)
Multiple sclerosis (99)
NASH (16)
Neurodegenerative disease (116)
Neuropsychiatric disorders (32)
Neuroscience (2139)
NextGen: Class of 2025 (6543)
Non-profit (4502)
Now hiring (47)
Obesity (429)
Opinion (217)
Ovarian cancer (101)
Pain (107)
Pancreatic cancer (121)
Parkinson's disease (187)
Partnered (22)
Patents (301)
Patient recruitment (168)
Peanut (50)
People (58390)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (21137)
Phase II (29886)
Phase III (22126)
Pipeline (1643)
Policy (200)
Postmarket research (2569)
Preclinical (9007)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (461)
Real estate (6006)
Recruiting (67)
Regulatory (22816)
Reports (50)
Research institute (2339)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (88)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3634)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (785)
Venture capital (55)
Weight loss (258)
Women's health (47)
Worklife (16)
Date
Today (83)
Last 7 days (356)
Last 30 days (1832)
Last 365 days (31413)
2025 (16977)
2024 (35565)
2023 (40474)
2022 (51633)
2021 (56244)
2020 (54471)
2019 (46898)
2018 (35313)
2017 (32507)
2016 (31949)
2015 (38017)
2014 (31842)
2013 (26766)
2012 (28943)
2011 (29608)
2010 (27666)
Location
Africa (730)
Alabama (66)
Alaska (7)
Arizona (246)
Arkansas (14)
Asia (39176)
Australia (6344)
California (7479)
Canada (2370)
China (693)
Colorado (324)
Connecticut (321)
Delaware (193)
Europe (84906)
Florida (1132)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (641)
India (27)
Indiana (362)
Iowa (17)
Japan (230)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1034)
Massachusetts (5597)
Michigan (246)
Minnesota (454)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2100)
New Mexico (29)
New York (2101)
North Carolina (1132)
North Dakota (8)
Northern California (3290)
Ohio (236)
Oklahoma (16)
Oregon (35)
Pennsylvania (1617)
Puerto Rico (18)
Rhode Island (36)
South America (1111)
South Carolina (34)
South Dakota (1)
Southern California (2796)
Tennessee (126)
Texas (1134)
United States (27845)
Utah (220)
Virginia (190)
Washington D.C. (73)
Washington State (644)
West Virginia (4)
Wisconsin (66)
712,704 Results for "asklepios biopharmaceutical inc askbio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders
May 27, 2025
·
11 min read
Drug Development
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.
February 16, 2024
·
10 min read
Drug Development
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the first patient has been randomized at the Ohio State University Wexner Medical Center in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P).
November 17, 2023
·
10 min read
Press Releases
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies
September 25, 2024
·
4 min read
Business
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).
January 9, 2023
·
5 min read
Bio NC
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress
Asklepios BioPharmaceutical, Inc. today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.
October 23, 2023
·
9 min read
Press Releases
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
May 22, 2025
·
4 min read
Press Releases
1Elevan Biopharmaceuticals, Inc. Announces the Development of Its Next-Generation Peptide Therapeutics Headquarters in Fishers, Indiana
June 18, 2025
·
3 min read
Drug Development
AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in Phase 1 / Phase 2 LION-CS101 clinical trial of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
August 3, 2023
·
8 min read
Press Releases
Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
June 10, 2025
·
3 min read
1 of 71,271
Next
